Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary

Cardiff Oncology

29/02/2024 23:19

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 21 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -20 cents.  The mean expectation of four analysts for the
quarter was for a loss of 28 cents per share. Wall Street
expected results to range from -29 cents to -27 cents per share.
    * Revenue rose 21.9% to $156.00 thousand from a year ago;
analysts
expected $37.50 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 21 cents​.
    * The company reported a quarterly loss of $9.34 million.
    * Cardiff Oncology Inc shares had risen by 23.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiff Oncology
Inc is $8.50 
This summary was machine generated from LSEG data February 29 at
11:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.28          -0.21          Beat
 Sep. 30 2023      -0.28          -0.22          Beat
 Jun. 30 2023      -0.26          -0.25          Beat
 Mar. 31 2023      -0.23          -0.25          Missed